| Bioactivity | Conatumumab (AMG 655) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2) (Kd: 1 nM for the long form of DR5, 0.8 nM for the short form of DR5). Conatumumab induces apoptosis via caspase activation. Conatumumab can be used in the research of cancers. [1][2][3]. |
| Target | IC50: DR5 (<1 nM) |
| Invitro | Conatumumab (0-10 μg/mL，4 小时) 激活 Colo205、H-2122 和 MiaPaCa2 细胞中的 caspase-3/7[2]。Conatumumab (0-10 μg/mL，24 小时) 降低敏感肿瘤细胞系 (Colo205、H-2122 和 MiaPaCa2 细胞) 的细胞活力[2]。 Cell Viability Assay[2] Cell Line: |
| In Vivo | Conatumumab (0-100 μg，腹腔注射，每周两次) 抑制 Colo205、H2122 或 MiaPaCa2/T2 异种移植肿瘤的小鼠的肿瘤生长[2]。Conatumumab (2.5 μg，i.p.，每周 3 次) 增强化疗药物 (CPT11，HY- 16562) (80 mg/kg) 在 Colo 205 移植瘤中的抗肿瘤活性[2]。 Animal Model: |
| Name | Conatumumab |
| CAS | 896731-82-1 |
| Molar Mass | 145.65 (kDa) |
| Appearance | Liquid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Herbst RS, et al. A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin Cancer Res. 2010 Dec 1;16(23):5883-91. [2]. Kaplan-Lefko PJ, et al. Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types. Cancer Biol Ther. 2010 Apr 15;9(8):618-31. |